Drug Profile
AM 132 - Kyowa Hakko
Latest Information Update: 26 Oct 2006
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Antineoplastics
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 25 May 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 03 Mar 1998 Preclinical development for Cancer in Japan (Unknown route)